Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Wake Research Associates

Neither a doctor nor a teaching hospital

Research payments

$3,540,337

2,743 payments

Through program year 2025, Wake Research Associates is reported as receiving $3,540,337 in research payments, across 2,743 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $135,695 76
2024 Research $11,859 8
2023 Research $593,069 650
2022 Research $1,467,216 1,817
2021 Research $190,089 18
2020 Research $319,419 56
2019 Research $822,991 118

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $1,229,397 2,357 payments
  2. Allergan Inc. $679,611 69 payments
  3. Merck Sharp & Dohme Corporation $393,863 4 payments
  4. Genentech, Inc. $193,571 55 payments
  5. Regeneron Pharmaceuticals, Inc. $146,937 11 payments
  6. Mylan Inc. $103,241 20 payments
  7. Ipsen Innovation $101,855 55 payments
  8. Ipsen Pharma SAS $92,907 59 payments
  9. Boehringer Ingelheim International GmbH $74,334 22 payments
  10. Novo Nordisk AS $68,315 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $909,358 1,782 payments
  2. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $318,338 574 payments
  3. A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly with Influenza Vaccine in Adults 50 Years of Age or Older $207,925 2 payments
  4. PH 3 Pivotal LCL and GL and LCL - Useu $192,271 7 payments
  5. A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age $164,653 1 payment
  6. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $163,066 14 payments
  7. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 $146,937 11 payments
  8. Phase Iia US Pop W Sod 3125-201-002 $141,575 17 payments
  9. Mr-100A-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $103,241 20 payments
  10. A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults $101,540 52 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record